| Alejandro Anzaldua, MD | |
|
900 Ne 10th St, Fmc 2102, Oklahoma City, OK 73104-5420 | |
| (405) 271-2230 | |
| Not Available |
| Full Name | Alejandro Anzaldua |
|---|---|
| Gender | Male |
| Speciality | Family Medicine |
| Location | 900 Ne 10th St, Oklahoma City, Oklahoma |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013112044 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | Q2506 (Texas) | Secondary |
| 207Q00000X | Family Medicine | 25739 (Oklahoma) | Primary |
| Entity Name | Questcare Medical Services Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164574489 PECOS PAC ID: 6204739402 Enrollment ID: O20040127000697 |
News Archive
The American Academy of Neurology has developed a new tool to help doctors gauge how well they are caring for people with Parkinson's disease. The new quality measures are published in the November 30, 2010, issue of Neurology®, the medical journal of the American Academy of Neurology.
A drug that would be the first to target the cause of Huntington's disease (HD) is effective and safe when tested in mice and monkeys, according to data released today that will be presented at the American Academy of Neurology's 68th Annual Meeting in Vancouver, Canada, April 15 to 21, 2016.
Atopic dermatitis, or eczema, is a common skin disorder that usually starts by 5 years of age, but virtually all of the studies that have defined the immune changes underlying eczema and are directing new treatment options have been done in adult skin.
Cardiovascular Systems, Inc. (CSI), a medical device company developing and commercializing innovative interventional treatment systems for vascular disease, today reported financial results for its fiscal third quarter ended March 31, 2010.
› Verified 9 days ago
| Entity Name | Concord Medical Group Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083630610 PECOS PAC ID: 0446296818 Enrollment ID: O20050707000531 |
News Archive
The American Academy of Neurology has developed a new tool to help doctors gauge how well they are caring for people with Parkinson's disease. The new quality measures are published in the November 30, 2010, issue of Neurology®, the medical journal of the American Academy of Neurology.
A drug that would be the first to target the cause of Huntington's disease (HD) is effective and safe when tested in mice and monkeys, according to data released today that will be presented at the American Academy of Neurology's 68th Annual Meeting in Vancouver, Canada, April 15 to 21, 2016.
Atopic dermatitis, or eczema, is a common skin disorder that usually starts by 5 years of age, but virtually all of the studies that have defined the immune changes underlying eczema and are directing new treatment options have been done in adult skin.
Cardiovascular Systems, Inc. (CSI), a medical device company developing and commercializing innovative interventional treatment systems for vascular disease, today reported financial results for its fiscal third quarter ended March 31, 2010.
› Verified 9 days ago
| Entity Name | Concord Medical Group Of Texas Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750790762 PECOS PAC ID: 7810117223 Enrollment ID: O20141007002567 |
News Archive
The American Academy of Neurology has developed a new tool to help doctors gauge how well they are caring for people with Parkinson's disease. The new quality measures are published in the November 30, 2010, issue of Neurology®, the medical journal of the American Academy of Neurology.
A drug that would be the first to target the cause of Huntington's disease (HD) is effective and safe when tested in mice and monkeys, according to data released today that will be presented at the American Academy of Neurology's 68th Annual Meeting in Vancouver, Canada, April 15 to 21, 2016.
Atopic dermatitis, or eczema, is a common skin disorder that usually starts by 5 years of age, but virtually all of the studies that have defined the immune changes underlying eczema and are directing new treatment options have been done in adult skin.
Cardiovascular Systems, Inc. (CSI), a medical device company developing and commercializing innovative interventional treatment systems for vascular disease, today reported financial results for its fiscal third quarter ended March 31, 2010.
› Verified 9 days ago
| Entity Name | Concord North Texas Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952761173 PECOS PAC ID: 2860791688 Enrollment ID: O20160429000472 |
News Archive
The American Academy of Neurology has developed a new tool to help doctors gauge how well they are caring for people with Parkinson's disease. The new quality measures are published in the November 30, 2010, issue of Neurology®, the medical journal of the American Academy of Neurology.
A drug that would be the first to target the cause of Huntington's disease (HD) is effective and safe when tested in mice and monkeys, according to data released today that will be presented at the American Academy of Neurology's 68th Annual Meeting in Vancouver, Canada, April 15 to 21, 2016.
Atopic dermatitis, or eczema, is a common skin disorder that usually starts by 5 years of age, but virtually all of the studies that have defined the immune changes underlying eczema and are directing new treatment options have been done in adult skin.
Cardiovascular Systems, Inc. (CSI), a medical device company developing and commercializing innovative interventional treatment systems for vascular disease, today reported financial results for its fiscal third quarter ended March 31, 2010.
› Verified 9 days ago
| Entity Name | Guadalupe Emergency Medicine Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114425220 PECOS PAC ID: 0941561781 Enrollment ID: O20180219001747 |
News Archive
The American Academy of Neurology has developed a new tool to help doctors gauge how well they are caring for people with Parkinson's disease. The new quality measures are published in the November 30, 2010, issue of Neurology®, the medical journal of the American Academy of Neurology.
A drug that would be the first to target the cause of Huntington's disease (HD) is effective and safe when tested in mice and monkeys, according to data released today that will be presented at the American Academy of Neurology's 68th Annual Meeting in Vancouver, Canada, April 15 to 21, 2016.
Atopic dermatitis, or eczema, is a common skin disorder that usually starts by 5 years of age, but virtually all of the studies that have defined the immune changes underlying eczema and are directing new treatment options have been done in adult skin.
Cardiovascular Systems, Inc. (CSI), a medical device company developing and commercializing innovative interventional treatment systems for vascular disease, today reported financial results for its fiscal third quarter ended March 31, 2010.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Alejandro Anzaldua, MD 940 Stanton L Young Blvd, Bmsb 357, Oklahoma City, OK 73104-5020 Ph: () - | Alejandro Anzaldua, MD 900 Ne 10th St, Fmc 2102, Oklahoma City, OK 73104-5420 Ph: (405) 271-2230 |
News Archive
The American Academy of Neurology has developed a new tool to help doctors gauge how well they are caring for people with Parkinson's disease. The new quality measures are published in the November 30, 2010, issue of Neurology®, the medical journal of the American Academy of Neurology.
A drug that would be the first to target the cause of Huntington's disease (HD) is effective and safe when tested in mice and monkeys, according to data released today that will be presented at the American Academy of Neurology's 68th Annual Meeting in Vancouver, Canada, April 15 to 21, 2016.
Atopic dermatitis, or eczema, is a common skin disorder that usually starts by 5 years of age, but virtually all of the studies that have defined the immune changes underlying eczema and are directing new treatment options have been done in adult skin.
Cardiovascular Systems, Inc. (CSI), a medical device company developing and commercializing innovative interventional treatment systems for vascular disease, today reported financial results for its fiscal third quarter ended March 31, 2010.
› Verified 9 days ago
Alyssa Penick, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 608 Nw 9th St Ste 1100, Oklahoma City, OK 73102 Phone: 405-231-3000 | |
Dr. Carl Patrick Griffin, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 3555 Nw 58th St, Suite 801, Oklahoma City, OK 73112 Phone: 405-840-7003 Fax: 405-840-8221 | |
Dewey C Scheid, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 900 Ne 10th St, Oklahoma City, OK 73104 Phone: 405-271-4311 Fax: 405-271-2797 | |
Dr. Johnaqa Saidi, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 9220 S Pennsylvania Ave Ste A, Oklahoma City, OK 73159 Phone: 405-691-4497 Fax: 405-692-8807 | |
Mrs. Lauren Cathleen Hopkins, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3500 Nw 56th St Ste 100, Oklahoma City, OK 73112 Phone: 405-951-2855 | |
Dr. Gurdeep Singh Grewal, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 900 Ne 10th St, Oklahoma City, OK 73104 Phone: 405-271-4311 | |
Dr. Cynthia M Brennan, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 9100 N May Ave, Oklahoma City, OK 73120 Phone: 405-840-4456 Fax: 405-840-4295 |